上海生诺

Sino-Nordic Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, focusing on the development of innovative small molecule drugs for gastrointestinal diseases and oncology. The company's lead candidate is a potassium-competitive acid blocker (P-CAB) designed to treat acid-related disorders such as gastric ulcers and reflux esophagitis with superior efficacy compared to traditional proton pump inhibitors. Beyond gastroenterology, Sino-Nordic is advancing a pipeline of oncology therapeutics, including topoisomerase inhibitors. The company leverages a cross-border R&D model, integrating resources from China and Northern Europe to accelerate drug discovery and clinical validation.